Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 14/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 13/20 | 0.67 |
| ▸ | OPRD1 | P41143 | 11/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.67 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.48 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.48 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6780954 | 0.85 | OPRL1 (0.69) | OPRL1OPRM1OPRD1OPRK1CACNA2D1 | |
| SCHEMBL6777765 | 0.84 | OPRM1 (0.57) | OPRL1OPRM1OPRD1OPRK1CACNA2D1 | |
| SCHEMBL14635953 | 0.81 | OPRM1 (0.69) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL4173900 | 0.79 | OPRL1 (0.56) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL17048674 | 0.78 | OPRM1 (0.46) | OPRL1OPRM1OPRD1OPRK1CACNA2D1 | |
| SCHEMBL6011696 | 0.74 | OPRM1 (0.56) | OPRL1OPRM1OPRD1OPRK1CACNA2D1 | |
| SCHEMBL31557722 | 0.74 | OPRL1 (0.62) | OPRL1OPRM1OPRD1OPRK1NPC1 | |
| SCHEMBL6363940 | 0.74 | OPRL1 (0.73) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL20341703 | 0.74 | OPRM1 (0.47) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL6897442 | 0.73 | OPRL1 (0.52) | OPRL1OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831078-B1 | 3-aryl substituted having halo or alkylhalo groups; anxiety, epilepsy; presurgery muscle relaxant | VERNALIS RESEARCH LIMITED (GB) | 2004-12-14 | — | — | US | disclosed |
| EP-1049670-B1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS | VERNALIS RES LTD (GB) | 2002-07-17 | — | — | EP | disclosed |
| EP-1196165-A2 | AZETIDINE COMPOUNDS IN CNS AND EYE DISEASES | VERNALIS RESEARCH LIMITED (GB) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001007022-A2 | AZETIDINE COMPOUNDS IN CNS AND EYE DISEASES | VERNALIS RESEARCH LIMITED (GB) | 2001-02-01 | — | — | WO | disclosed |
| EP-1049670-A1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999037613-A1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 1999-07-29 | — | — | WO | disclosed |